The Next Step is an occasional series of conversations in which The Cancer Letter will focus on cancer researchers in the midst of transition from one position to another.
After getting the news that he and collaborator John Schiller have won the 2017 Lasker-DeBakey Clinical Medical Research Award, Douglas Lowy said that part of the credit belongs to the NCI intramural research program.
A SWOG study estimates that implementation of findings from that group's clinical trials has added 3.34 million years to the lives of cancer patients in the 60 years since its founding in 1956.
When former Vice President Joe Biden sought to convene and cajole cancer organizations into breaking down silos as part of the Cancer Moonshot, he frequently expressed frustration about reluctance on the part of cancer organizations to share data.
A recent proposal to delay reporting of device malfunctions to FDA will weaken the already inadequate medical device reporting system at the agency, said Rita Redberg, a professor of medicine and cardiologist at the University of California San Francisco.
Though NCI-MATCH and Pediatric MATCH are similar in structure, they represent different approaches to oncology.
Klausner spoke with Paul Goldberg, editor and publisher of The Cancer Letter.
NCI and ECOG-ACRIN officials said the NCI-MATCH trial will keep going, continuing to match patients with treatment arms based primarily on their molecular characteristics.
The first step in the NCI-MATCH trial—deciding how many patients to screen—was a guess.
Michael Birrer named director of the University of Alabama at Birmingham Comprehensive Cancer Center
Michael Birrer, an expert in early detection and treatment of gynecologic cancers, was named director of the University of Alabama at Birmingham Comprehensive Cancer Center.
